Perspectives on Alzheimer’s Disease Research from Worldwide’s Chief Medical & Scientific Officer
Michael Murphy, M.D., Ph.D., has been on the forefront of Alzheimer’s disease research since the advent of cholinesterase inhibitors as a cognitive therapeutic in the late 1970s. As Chief Medical & Scientific Officer of Worldwide Clinical Trials, Dr. Murphy provides a strategic leadership role in program and protocol design across multiple therapeutic areas, for both interventional and observational research. Dr. Murphy is responsible for the coordination of didactic and experiential training services for the Worldwide Fellowship program, which bears his name. He is the recipient of the Clinical Research & Excellence (CARE) Lifetime Achievement Award for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career. In addition, PharmaVoice selected him as one of 2017’s 100 Most Inspiring People in the life-sciences industry.